Comparative Pharmacology
Head-to-head clinical analysis: DYCILL versus DYNAPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYCILL versus DYNAPEN.
DYCILL vs DYNAPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin G benzathine is a slow-release parenteral formulation of penicillin G that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
Dynapen (dicloxacillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
250 mg orally every 6 hours or 500 mg orally every 12 hours.
250-500 mg orally every 6 hours for skin and soft tissue infections; up to 500 mg every 6 hours for respiratory tract infections.
None Documented
None Documented
0.5-1 hour; prolonged in renal impairment (up to 20 hours in severe cases).
0.5-1 hour in normal renal function; prolonged to 7-10 hours in anuria.
Renal: approx. 60-80% unchanged by glomerular filtration and tubular secretion. Biliary/fecal: minor (less than 10%).
Renal: 60-80% as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal: <10%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic